British American Tobacco p.l.c.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTI research report →
Range $40 – $40
Price Chart
About the company
British American Tobacco p. l. c.
- CEO
- Tadeu Marroco
- IPO
- 1980
- Employees
- 47,797
- HQ
- London, GL, GB
AI snapshot
Six angles, distilled from the data.
The stock is still in a corrective regime after peaking near 67.3, with price below both the 50-day and 200-day moving averages. That keeps the longer-term trend mixed, though the share price remains well above the 52-week low and closer to the middle of its annual range than a breakdown zone.
Street sentiment is constructive but not emphatic: the consensus sits at Buy with a 70.2 average target, implying meaningful upside from current levels. Recent changes have been mixed, with Morgan Stanley upgrading to Overweight, BTIG initiating at Buy, and RBC keeping an Underperform call in place.
The earnings backdrop is uneven but not broken. BTI has beaten in only 1 of the last 7 reported quarters, while next-year EPS estimates point to 5.2214 versus 3.93 TTM, so shareholders should watch whether margin discipline and cash conversion support that step-up.
No notable discretionary insider buying or selling in recent quarters. The only listed transaction is a 2022 director-related other entry tied to BT DE Investments Inc., which does not read like a fresh market signal.
Profitability remains strong, with a 24.99% net margin, 34.91% operating margin, and 82.7% gross margin. Revenue grew 1.4% year over year, while earnings fell 28.6%, so the setup favors a business that still throws off cash but needs profit stabilization.
BTI stands out for scale, cash generation, and a low-beta profile, but tobacco peers with cleaner growth narratives may command more enthusiasm. At 10.69x earnings, valuation remains modest versus the broader staples complex and leaves room for multiple support if execution steadies.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $122.52B
- P/E
- 14.25
- Fwd P/E
- 15.74
- PEG
- 0.13
- P/S
- 3.48
- P/B
- 1.86
- EV/EBITDA
- 9.85
- Div Yield
- 5.83%
- Gross Margin
- 60.16%
- Op Margin
- 37.62%
- Net Margin
- 24.99%
- ROE
- 13.38%
- ROIC
- 7.62%
Latest fiscal year · YoY change
- Revenue
- $25.61B-1.0%
- Gross Profit
- $21.38B-0.2%
- Op Income
- $10.00B
- Net Income
- $7.76B+153.1%
- EPS
- $3.51+156.2%
- OCF Growth
- -37.4%
- FCF Growth
- -39.2%
- 52W High
- $67.30
- 52W Low
- $49.88
- 50D MA
- $60.19
- 200D MA
- $59.02
- Beta
- 0.13
- RSI (14)
- 42
- Avg Volume
- 4.20M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BAT said H1 results were in line with expectations, with strong U.S. multi-category and Velo momentum, and raised full-year EPS guidance to the middle of its 5% to 8% range.· July 30, 2026
- H1 revenue grew 2.9%, adjusted gross profit rose 3.8%, adjusted profit from operations increased 3.5%, and adjusted diluted EPS was up 7.9% (constant currency).
- Smokeless reached 19.8% of group revenue, up 160 bps year over year, with 4.1 million more smokeless consumers over 12 months.
- New category revenue accelerated 18%, led by Modern Oral up 66%; category contribution rose 55% to GBP 269 million.
- The company expects H2 profit to be stronger, helped by AME/APMEA improvement, Fit2Win savings, and more investment in U.S. Vapor and combustibles.
- Full-year EPS guidance was upgraded to the middle of the 5% to 8% range; leverage is expected to be within 2 to 2.5x by year-end.
- BAT reiterated GBP 1.3 billion of share buybacks in 2026 and said it remains on track to generate more than GBP 50 billion of free cash flow by 2030.
Reported on a constant currency adjusted basis, group revenue increased 2.9%, adjusted gross profit rose 3.8%, adjusted profit from operations grew 3.5%, and adjusted diluted EPS increased 7.9%. New categories delivered 18% revenue growth, with Modern Oral up 66% and Vapour up 5.3%, while heated products revenue fell nearly 12%; category contribution reached GBP 269 million, up 55%. Combustibles revenue rose 2.1% with price/mix up 6.8%, while combustible volumes fell 4.7%. Group operating margin was 43.7%, up 30 bps. Adjusting items included approximately GBP 800 million primarily from U.S. trademark amortization, a GBP 370 million Fit2Win-related one-off, and a GBP 149 million credit from historical litigation settlement. For the full year, management expects net finance cost of around GBP 1.65 billion, an underlying tax rate of 24% to 25%, revenue and operating profit at the lower end of the previously guided range, and EPS growth towards the middle of the 5% to 8% range. The company also said it expects to be within its 2 to 2.5x leverage corridor by year-end.
Tadeu Marroco framed the quarter as evidence that BAT’s transformation is gaining momentum, especially in smokeless and in the U.S. multi-category portfolio. He emphasized that BAT is now the fastest-growing company in total nicotine, with Velo and Vuse strengthening leadership positions, and said the business is returning to its algorithm after a period of investment and transition. His tone was confident but disciplined, stressing that the company is investing where returns are strongest and focusing on long-term sustainable growth rather than maximizing short-term results.
Javed Iqbal highlighted that H1 results were in line with expectations on a constant currency basis, with stronger performance from the U.S. and new categories. He called out the main adjusting items: about GBP 800 million from U.S. trademark amortization, GBP 370 million of Fit2Win-related adjustments, and a GBP 149 million litigation credit, and said the group posted a 43.7% operating margin, up 30 bps. He also guided to net finance cost of around GBP 1.65 billion, a 24% to 25% tax rate, leverage within 2 to 2.5x by year-end, and full-year EPS growth in the middle of the 5% to 8% range, supported by strong cash conversion above 95% for the full year.
Analysts focused on the sustainability of U.S. Vapor enforcement tailwinds, the rollout pace and economics of Velo Max, U.S. combustibles outperformance versus the algorithm, and whether European vape weakness and market exits were complete. Management said enforcement is helping the legal Vapor market, but the bigger change should come from more level playing field and FDA prioritization guidance; Vuse flavor rollout will start in Q3 in about 25,000 outlets and then expand in Q4. On U.S. combustibles, BAT said H1 benefited from trade movements and that second-half performance should moderate closer to the algorithm as it increases investment and lapping gets tougher; on market exits in Vapor, management said most actions are already taken but some H2 impact may still remain.
The bull case from the call is that BAT’s smokeless transition is clearly gaining scale, with smokeless now nearly one-fifth of group revenue and Modern Oral/Vuse/Velo posting very strong growth. Management sounded increasingly confident that regulatory changes, especially in U.S. Vapor and global Modern Oral, can support longer-term category expansion and margin improvement.
The main risks discussed were slower-than-expected recovery in APMEA, ongoing pressure in heated products, and continued competition and illicit activity in U.S. Vapor and cigarettes. Management also said H2 will be tougher because strong U.S. inventory-driven growth will not repeat, combustibles investment will rise, and some market exits and regulatory changes will continue to weigh on reported numbers.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 2.16B
- Float Shares
- 2.15B
of shares held by institutions
908 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BTI, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lisa McClainHouse · MI09 | Sell | Sep 25, 25 | Filing → |
| Lisa McClainHouse · MI09 | Buy | Aug 4, 25 | Filing → |
| Lisa McClainHouse · MI09 | Buy | Jun 17, 25 | Filing → |
| Lisa McClainHouse · MI09 | Sell | Jun 24, 25 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jul 10, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Buy | Feb 27, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jan 13, 23 | Filing → |
| Virginia FoxxHouse · NC05 | Buy | Mar 31, 22 | Filing → |
| Virginia FoxxHouse · NC05 | Buy | Mar 29, 22 | Filing → |
| Virginia FoxxHouse · NC05 | Sell | Nov 2, 22 | Filing → |
| Virginia FoxxHouse · NC05 | Buy | Aug 23, 22 | Filing → |
| Virginia FoxxHouse · NC05 | Buy | Jul 14, 22 | Filing → |
| Virginia FoxxHouse · NC05 | Buy | Jul 29, 22 | Filing → |
| Virginia FoxxHouse · NC05 | Buy | Jun 30, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Capital International Investors | 49.13M | ▲ 318.83K |
| Fmr LLC | 44.16M | ▲ 7.47M |
| Capital Research Global Investors | 30.33M | ▼ 632.06K |
| Gqg Partners LLC | 24.57M | ▼ 3.12M |
| Blackrock, Inc. | 20.16M | ▲ 1.01M |
| Bank Of America Corp | 10.53M | ▲ 798.14K |
| Capital World Investors | 9.74M | ▲ 49.69K |
| Morgan Stanley | 7.71M | ▲ 2.51M |
| Orbis Allan Gray Ltd | 7.39M | ▼ 320.59K |
| Jpmorgan Chase & Co | 5.39M | ▼ 425.02K |
| Wells Fargo & Company/Mn | 4.87M | ▲ 224.99K |
| Natixis Advisors, L.P. | 4.48M | ▲ 329.94K |
Held by 41 ETFs
Biggest fund positions in BTI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 14, 22 | BT DE Investments Inc. | other | 37,670,540 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BTI coverage
Recent articles, reports, and earnings notes.

British American Tobacco (BTI): Smokeless Growth Is Gaining Traction
British American Tobacco is a medium-term Buy as combustibles keep generating cash while smokeless products, led by Velo, show real operating momentum. The stock looks reasonably valued with a fair value estimate of $68.

British American Tobacco p.l.c. (BTI) rises 6.5% on buybacks
British American Tobacco p.l.c. (BTI) rises sharply as buyback support, stronger New Category momentum, and a favorable defensive-sector backdrop lift sentiment. The stock’s move stands out for a low-beta tobacco name, with investors still focused on income, valuation, and capital returns.

British American Tobacco (BTI): Cash Flow, Buybacks and Smokeless Growth
British American Tobacco offers a defensive income-and-value setup with strong cash flow, improving smokeless economics, and a Buy rating. The report highlights a 12.75x trailing P/E, rising New Categories contribution, and continued capital returns.
Want a deeper read on BTI?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Charlotte's Web Reports Second Quarter 2026 Financial Results
newsfilecorp.com · Aug 13
These 4 Dividend Stocks Yield 8%. Only Roth Owners Keep All of It
247wallst.com · Aug 12
ITC Infotech Strengthens Strategic Tech Partnership With British American Tobacco (BAT) in New Multi-year Mandate
businesswire.com · Aug 12
British American Tobacco Isn't Cheap Enough To Justify The Risk
seekingalpha.com · Aug 8
British American Tobacco p.l.c. (BTI) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 5
British American Tobacco: The Right Kind Of Growth
seekingalpha.com · Jul 31
British American Tobacco p.l.c. (BTI) Q2 2026 Earnings Call Transcript
seekingalpha.com · Jul 30
British American Tobacco H1 Earnings Call Highlights
marketbeat.com · Jul 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed August 16, 2026 · Live quote · Not investment advice